September 2020- Volume 16, Issue 8

In this Issue

Business & Government Policy

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

Q&A: Another look at aducanumab

Q&A: Another look at aducanumab

ProMIS Neurosciences’ CMO talks with DDN about why Biogen restarted its Alzheimer’s disease program

Feature

Focus Feature on Neuroscience

Focus Feature on Neuroscience

The Society for Nueroscience meeting may have been called off this year, but DDN has a large roundup of recent news of neurological R&D to share in its place, from aging insights via sea urchins to machine learning advances to putting antibodies to work in treating neurodegeneration (and more)

Special Reports

Commentary

Innovating scientific conferences

Innovating scientific conferences

More meetings are going virtual, and that may very well be a good thing even after COVID is no longer a pandemic

Editor's Focus

Editor’s Focus: Alzheimer’s looms large in neuroscience

Editor’s Focus: Alzheimer’s looms large in neuroscience

Editor’s Focus: Alzheimer’s looms large in neuroscience

Market research suggests that neurology-related pharma and biotech R&D is going to be dominated by Alzheimer's disease for some time

Clinical Trials

Hopes on the rise in wake of ASCENT data

Hopes on the rise in wake of ASCENT data

Immunomedics shares strong data for Trodelvy in triple-negative breast cancer

Mighty micro PEA

Mighty micro PEA

Prospective COVID-19 treatment uses cannabinoid approach

Research highlights potential of Akero’s NASH candidate

Research highlights potential of Akero’s NASH candidate

Patients treated with efruxifermin show improvements in markers of insulin sensitivity and lipoprotein metabolism

ISA101b and Libtayo vs. oropharyngeal cancer

ISA101b and Libtayo vs. oropharyngeal cancer

ISA Pharmaceuticals strengthens strategic immuno-oncology collaboration with Regeneron

In pursuit of emergency authorization

In pursuit of emergency authorization

RedHill Biopharma accelerates Phase 2/3 COVID-19 drug opaganib program

Discovery

Welcoming the fourth wave of drug discovery

Welcoming the fourth wave of drug discovery

Amgen executive forecasts multispecific drugs as the next key movement

An ‘exquisitely selective’ tool

An ‘exquisitely selective’ tool

Mission Therapeutics and Imperial College London report on deubiquitylating enzyme probe

Human-on-a-Chip system models Alzheimer’s

Human-on-a-Chip system models Alzheimer’s

Publication validates potential of drug discovery platform to study early stages of disease pathology

Where AI meets biology

Where AI meets biology

TARA and VentAI collaborate on drug discovery

Quantum (computing) gains

Quantum (computing) gains

Drug discovery expected to be one of the first beneficiaries of technology

Preclinical

A (natural) killer match

A (natural) killer match

Kiadis, Sanofi ink license agreement for natural killer therapeutics

Can a vaccine prevent type 1 diabetes?

Can a vaccine prevent type 1 diabetes?

Provention Bio advances work on coxsackievirus B vaccine

Diagnostics

Trying to meet coronavirus demands

Trying to meet coronavirus demands

NIH awards nearly $249M into new COVID-19 testing technologies

Critical for cancer

Critical for cancer

U.K.-Italy collaboration aims for precision oncology at scale

Antigens for SARS-CoV-2

Antigens for SARS-CoV-2

LGC acquires NAC, one of first to offer antigens for novel coronavirus

Exhaled biomarkers reveal lung disease

Exhaled biomarkers reveal lung disease

Nanoparticles create a ‘breath signal’ that could be used to diagnose infectious or genetic diseases

Contract Services

Integrated services for COVID and more

Integrated services for COVID and more

CaprionX-HistoGeneX and Viroclinics-DDL to offer complementary services for infectious disease research and therapeutics

Mid-Size CRO steps up

Mid-Size CRO steps up

Pharm-Olam positioning organization for growth trajectory

A faster new product pathway

A faster new product pathway

LGM Pharma acquires Nexgen Pharma’s CDMO operations

Research & Development

Tracking down gene fusions

Tracking down gene fusions

Stanford researchers use single-cell statistical modeling method to go after cancer

Leveraging lentivirals

Leveraging lentivirals

Magenta Therapeutics joins with AVROBIO to evaluate a combination approach to gene therapy

Gaining ground with Gemini

Gaining ground with Gemini

In-silico patient model moves industry a step closer to understanding human disease
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Drug Discovery News November 2024 Issue

Latest Issue  

• Volume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue